Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) deputy chairman Harry Karelis speaks to Proactive's Andrew Scott soon after announcing a strategic consolidation of its operations which sees leadership of the company transfer to the US-based team, with Dr Oludare Odumosu assuming the role of global managing director. ''We have a two-pronged approach, multiple shots on goal and multiple revenue streams which definitely de-risks the company'', he says.
Zelira Therapeutics sees 'multiple shots on goal' with a number of revenue streams
